Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ)
CNY 8.23
(0.61%)
CNY 8.23
(0.61%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 998.26 Million CNY | -4.29% |
| 2022 | 1.04 Billion CNY | 195.48% |
| 2021 | 353 Million CNY | 443.08% |
| 2020 | 65 Million CNY | -77.91% |
| 2019 | 294.3 Million CNY | 695.43% |
| 2018 | 37 Million CNY | -60.22% |
| 2017 | 93 Million CNY | 50.52% |
| 2016 | 61.78 Million CNY | -5.47% |
| 2015 | 65.36 Million CNY | 151.38% |
| 2014 | 26 Million CNY | -43.48% |
| 2013 | 46 Million CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 742.37 Million CNY | 0.0% |
| 2024 Q1 | 998.26 Million CNY | 0.0% |
| 2024 Q2 | 742.37 Million CNY | -25.63% |
| 2023 Q3 | 1 Billion CNY | -8.97% |
| 2023 Q4 | 998.26 Million CNY | -0.59% |
| 2023 Q1 | 962.04 Million CNY | -7.77% |
| 2023 FY | 998.26 Million CNY | -4.29% |
| 2023 Q2 | 1.1 Billion CNY | 14.67% |
| 2022 Q4 | 1.04 Billion CNY | 4.42% |
| 2022 Q3 | 998.87 Million CNY | -0.21% |
| 2022 Q2 | 1 Billion CNY | 75.31% |
| 2022 FY | 1.04 Billion CNY | 195.48% |
| 2022 Q1 | 571 Million CNY | 61.76% |
| 2021 Q1 | 102 Million CNY | 56.92% |
| 2021 Q3 | 237 Million CNY | 229.17% |
| 2021 Q4 | 353 Million CNY | 48.95% |
| 2021 FY | 353 Million CNY | 443.08% |
| 2021 Q2 | 72 Million CNY | -29.41% |
| 2020 Q1 | 217.06 Million CNY | -26.25% |
| 2020 FY | 65 Million CNY | -77.91% |
| 2020 Q4 | 65 Million CNY | 3.17% |
| 2020 Q3 | 63 Million CNY | -62.34% |
| 2020 Q2 | 167.27 Million CNY | -22.94% |
| 2019 Q2 | 373 Million CNY | 10.69% |
| 2019 Q1 | 336.99 Million CNY | 810.8% |
| 2019 FY | 294.3 Million CNY | 695.43% |
| 2019 Q4 | 294.3 Million CNY | -14.98% |
| 2019 Q3 | 346.14 Million CNY | -7.2% |
| 2018 Q3 | 91 Million CNY | -1.09% |
| 2018 Q2 | 92 Million CNY | 0.0% |
| 2018 Q1 | 92 Million CNY | -1.08% |
| 2018 FY | 37 Million CNY | -60.22% |
| 2018 Q4 | 37 Million CNY | -59.34% |
| 2017 Q3 | 30 Million CNY | 0.0% |
| 2017 Q4 | 93 Million CNY | 210.0% |
| 2017 Q2 | 30 Million CNY | -40.0% |
| 2017 Q1 | 50 Million CNY | 0.0% |
| 2017 FY | 93 Million CNY | 50.52% |
| 2016 Q2 | 35.36 Million CNY | -45.9% |
| 2016 Q4 | - CNY | -100.0% |
| 2016 Q3 | 35.36 Million CNY | 0.0% |
| 2016 Q1 | 65.36 Million CNY | 0.0% |
| 2016 FY | 61.78 Million CNY | -5.47% |
| 2015 Q3 | 49.2 Million CNY | 0.0% |
| 2015 FY | 65.36 Million CNY | 151.38% |
| 2015 Q4 | 65.36 Million CNY | 32.85% |
| 2015 Q1 | - CNY | -100.0% |
| 2015 Q2 | 49.2 Million CNY | 0.0% |
| 2014 Q4 | 26 Million CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 FY | 26 Million CNY | -43.48% |
| 2013 FY | 46 Million CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |